Side-by-side comparison of AI visibility scores, market position, and capabilities
Reached $1B valuation (2026). Automates specialty drug prior auth, access barriers, and copay assistance for providers. Targets $500B+ specialty drug access bottleneck.
Tandem is a specialty drug access automation platform that has reached a $1 billion valuation in 2026, providing AI-powered automation of the full specialty pharmaceutical access workflow for healthcare providers — prior authorization submissions, access barrier management, copay assistance enrollment, and patient assistance program identification. The platform targets the $500+ billion specialty drug market where access friction is the primary barrier preventing patients from receiving prescribed medications.
a2z Radiology AI raised $20M in 2025 for its whole-body AI that simultaneously screens for 24+ conditions across CT scans — from incidental cancers to cardiovascular risk — in a single automated read.
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disease, aortic aneurysm, bone density loss, and organ abnormalities. The AI acts as a second reader that radiologists can use to catch incidental findings that fall outside the primary reason for a scan — a major source of missed diagnoses.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.